癌症试验影响力的证据:2014年英国研究卓越框架的启示
多数为III期随机对照试验和乳腺癌患者招募试验。癌症试验最常见的影响力体现在政策层面,尤其是试验结果被临床指南引用;对健康结果和经济的影响较少且多为预测而非实证。
要点
- 癌症试验影响力最常见于政策层面,尤其是被临床指南引用。
- 对健康结果和经济的影响报告较少,且健康结果多为预测而非实证。
- 案例中鲜有试验者努力最大化试验影响力的描述。
核心结论
- 癌症试验的影响力证据主要集中在政策引用,健康结果和经济影响证据不足且多为预测。
- 未来评估应注重实证影响、明确受益者和结果使用过程,并明确责任与资源。
研究设计与样本
- 基于2014年英国研究卓越框架(REF)的6637份影响力案例研究,手动内容分析其中涉及癌症试验的案例。
主要发现
- 最常见的影响力为政策影响,尤其是试验结果被临床指南引用。
- 对健康结果和经济的影响较少,健康结果多为预测而非实证。
- 案例中鲜有试验者努力最大化试验影响力的描述。
临床怎么用
- 在试验设计和实施中应主动规划影响力证据的收集,注重实证健康结果和经济影响。
- 明确试验结果的受益者和使用过程,以增强影响力叙事。
局限性
- 仅基于REF2014的案例研究,可能不全面代表所有癌症试验的影响力。
- 案例研究为回溯性描述,影响力证据多为预测而非实证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: An impactful clinical trial will have real-life benefits for patients and society beyond the academic environment. This study analyses case studies of cancer trials to understand how impact is evidenced for cancer trials and how impact evaluation can be more routinely adopted and improved. METHODS: The United Kingdom (UK) Government allocates research funding to higher-education institutions based on an assessment of the institutions' previous research efforts, in an exercise known as the Research Excellence Framework (REF). In addition to each institution's journal publications and research environment, for the first time in 2014, allocation of funding was also dependent on an evaluation of the wider, societal impact of research conducted. In the REF2014, impact assessment was performed by evaluation of impact case studies. In this study, case studies (n = 6637) submitted by institutions for the REF2014 were accessed and those focussing on cancer trials were identified. Manual content analysis was then used to assess the characteristics of the cancer trials discussed in the case studies, the impact described and the methods used by institutions to demonstrate impact. RESULTS: Forty-six case studies describing 106 individual cancer trials were identified. The majority were phase III randomised controlled trials and those recruiting patients with breast cancer. A list of indicators of cancer trial impact was generated using the previous literature and developed inductively using these case studies. The most common impact from a cancer trial identified in the case studies was on policy, in particular citation of trial findings in clinical guidelines. Impact on health outcomes and the economy were less frequent and health outcomes were often predicted rather than evidenced. There were few descriptions identified of trialists making efforts to maximise trial impact. DISCUSSION: Cancer trial impact narratives for the next REF assessment exercise in 2021 can be improved by evidencing actual rather than predicted Impact, with a clearer identification of the beneficiaries of cancer trials and the processes through which trial results are used. Clarification of the individuals responsible for performing impact evaluations of cancer trials and the provision of resources to do so needs to be addressed if impact evaluation is to be sustainable.
引用
- Hanna CR, Gatting LP, Boyd KA, et al. Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework. Trials. 2020. PMID: 32503612. doi:10.1186/s13063-020-04425-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。